港股異動 | 中國光大水務(1857.HK)逆勢漲5% 股價創一年新高
格隆匯3月4日丨中國光大水務(1857.HK)逆勢拉昇4.96%,報1.48港元創一年新高,成交額放大至3087萬港元,總市值42.34億港元。中國光大水務2月底公佈業績公吿,截至2020年12月31日止年度,該公司錄得收入約為56.63億港元,同比增長2.03%;股東應占盈利約為10.24億港元,同比大增長22.89%。日前全資附屬完成購買天津環塘污水處理項目65%股權,對今年以及後年度,公司認為這個行業的併購整合還是有很大機會的。公司相信在2021年海外業務特別是在技術服務,一些委託運營等方面都會恢復起來,對此公司也在積極在中東、南亞、中東歐這邊的話來開展相應的業務。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.